Overview

Temsirolimus in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Status:
Completed

Trial end date:
2012-01-01

Target enrollment:

Participant gender:

Summary

This phase II trial is studying the side effects and how well temsirolimus works in treating patients with refractory or recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Phase:

Phase 2

Details

Lead Sponsor:

National Cancer Institute (NCI)

Collaborator:

Gynecologic Oncology Group

Treatments:

Everolimus
Sirolimus